Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Dyal Co. is an independent boutique investment bank that provides strategic advisory services, primarily focusing on large-scale mergers and acquisitions within the life sciences, pharmaceutical, and healthcare sectors. Founded in 2016 by Gordon Dyal, the former Co-Chairman of Investment Banking at Goldman Sachs, the firm has established itself as a premier advisor for complex, high-value pharmaceutical transactions. Dyal Co. has played a pivotal role in several industry-defining deals, including advising AstraZeneca on its 39 billion USD acquisition of Alexion Pharmaceuticals and Novartis on its 9.7 billion USD purchase of The Medicines Company. The firm also provided counsel to Gilead Sciences during its 21 billion USD acquisition of Immunomedics. Known for its discretion and deep industry relationships, Dyal Co. operates at the intersection of high finance and global healthcare strategy.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Dyal Co..